Abbott Laboratories Expects H2 Growth Driven by Product Launches, Nutrition Recovery, RBC Says

MT Newswires Live01-24

Abbott Laboratories (ABT) expects growth to accelerate in the second half of 2026, supported by new product launches, recovering Nutrition and Diagnostics businesses and easier year-over-year comparisons, RBC Capital Markets said.

The brokerage said in a Thursday note that the near-term challenges in Diagnostics from Chinese volume-based procurement and internal initiatives in Nutrition are likely to persist in the first half. However, RBC said the issues are temporary.

Abbott guided to 2026 organic revenue growth of 6.5% to 7.5%, which is below RBC and consensus estimates. The company also projected adjusted EPS of $5.55 to $5.80 roughly in line with forecasts.

MedTech grew 10.4% organically in Q4, which was slightly below RBC's estimate. Established Pharmaceuticals rose 7%. These results supported total organic growth of 3.8% but excluding COVID-related sales.

The brokerage said that the expectations have now reset and upside surprises in the second half could come from the US launch of the VOLT system in Electrophysiology. Additional growth could come from Structural Heart, Diabetes and potential M&A in Diagnostics and MedTech.

Management remains committed to delivering double-digit EPS growth and cited confidence in operational execution and long-term demand trends, according to the note.

RBC maintained an outperform rating for Abbott and lowered its price target to $135 from $147.

Price: 107.66, Change: -0.95, Percent Change: -0.88

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2605340237?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-24 01:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2605340237","market":"fut","top_or_hot":-1,"title":"Abbott Laboratories Expects H2 Growth Driven by Product Launches, Nutrition Recovery, RBC Says","media":"MT Newswires Live","content":"<html><body><p> Abbott Laboratories (ABT) expects growth to accelerate in the second half of 2026, supported by new product launches, recovering Nutrition and Diagnostics businesses and easier year-over-year comparisons, RBC Capital Markets said.</p><p>The brokerage said in a Thursday note that the near-term challenges in Diagnostics from Chinese volume-based procurement and internal initiatives in Nutrition are likely to persist in the first half. However, RBC said the issues are temporary.</p><p>Abbott guided to 2026 organic revenue growth of 6.5% to 7.5%, which is below RBC and consensus estimates. The company also projected adjusted EPS of $5.55 to $5.80 roughly in line with forecasts.</p><p>MedTech grew 10.4% organically in Q4, which was slightly below RBC's estimate. Established Pharmaceuticals rose 7%. These results supported total organic growth of 3.8% but excluding COVID-related sales.</p><p>The brokerage said that the expectations have now reset and upside surprises in the second half could come from the US launch of the VOLT system in Electrophysiology. Additional growth could come from Structural Heart, Diabetes and potential M&amp;A in Diagnostics and MedTech.</p><p>Management remains committed to delivering double-digit EPS growth and cited confidence in operational execution and long-term demand trends, according to the note.</p><p>RBC maintained an outperform rating for Abbott and lowered its price target to $135 from $147.</p><p>Price: 107.66, Change: -0.95, Percent Change: -0.88</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Abbott Laboratories Expects H2 Growth Driven by Product Launches, Nutrition Recovery, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbott Laboratories Expects H2 Growth Driven by Product Launches, Nutrition Recovery, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-01-24 01:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Abbott Laboratories (ABT) expects growth to accelerate in the second half of 2026, supported by new product launches, recovering Nutrition and Diagnostics businesses and easier year-over-year comparisons, RBC Capital Markets said.</p><p>The brokerage said in a Thursday note that the near-term challenges in Diagnostics from Chinese volume-based procurement and internal initiatives in Nutrition are likely to persist in the first half. However, RBC said the issues are temporary.</p><p>Abbott guided to 2026 organic revenue growth of 6.5% to 7.5%, which is below RBC and consensus estimates. The company also projected adjusted EPS of $5.55 to $5.80 roughly in line with forecasts.</p><p>MedTech grew 10.4% organically in Q4, which was slightly below RBC's estimate. Established Pharmaceuticals rose 7%. These results supported total organic growth of 3.8% but excluding COVID-related sales.</p><p>The brokerage said that the expectations have now reset and upside surprises in the second half could come from the US launch of the VOLT system in Electrophysiology. Additional growth could come from Structural Heart, Diabetes and potential M&amp;A in Diagnostics and MedTech.</p><p>Management remains committed to delivering double-digit EPS growth and cited confidence in operational execution and long-term demand trends, according to the note.</p><p>RBC maintained an outperform rating for Abbott and lowered its price target to $135 from $147.</p><p>Price: 107.66, Change: -0.95, Percent Change: -0.88</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1057294990.SGD","symbol_name":"Blackrock World Healthscience A2 SGD-H","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2605340237","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2605340237","pubTimestamp":1769188469,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Abbott Laboratories (ABT) expects growth to accelerate in the second half of 2026, supported by new product launches, recovering Nutrition and Diagnostics businesses and easier year-over-year comparis","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4568":"美国抗疫概念","BK4588":"碎股","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1691799644.USD":"Amundi Funds Polen Capital Global Growth A2 (C) USD","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU2237957902.USD":"NIKKO AM GLOBAL EQUITY \"F\" (USD) ACC","SGXZ41872573.SGD":"ALLIANZ SGD INCOME PLUS \"AM\" (SGD) INC","SG9999002224.SGD":"Allianz Global High Payout SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4581":"高盛持仓","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","ABT":"雅培","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","BK4504":"桥水持仓","BK4585":"ETF&股票定投概念","LU1989763427.SGD":"CPR Invest - Food For Generations A2 Acc SGD-H","LU1721429402.USD":"BNP PARIBAS SMART FOOD \"C\" (USD) ACC","LU1721429741.USD":"BNP PARIBAS SMART FOOD \"CRH\" (USD) INC","ABT.AU":"Abundant Produce","LU0122379950.USD":"贝莱德世界健康科学A2","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1989763690.USD":"东方汇理世代食品基金A2 Acc","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK4566":"资本集团","LU0058720904.USD":"联博国际健康护理基金A","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","BK4082":"医疗保健设备","BK4592":"伊斯兰概念","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC"},"translate_title":"加拿大皇家银行表示，雅培实验室预计下半年增长将受到产品发布和营养恢复的推动","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABT.AU":1,"ABT":1.5},"content_text":"Abbott Laboratories (ABT) expects growth to accelerate in the second half of 2026, supported by new product launches, recovering Nutrition and Diagnostics businesses and easier year-over-year comparisons, RBC Capital Markets said.The brokerage said in a Thursday note that the near-term challenges in Diagnostics from Chinese volume-based procurement and internal initiatives in Nutrition are likely to persist in the first half. However, RBC said the issues are temporary.Abbott guided to 2026 organic revenue growth of 6.5% to 7.5%, which is below RBC and consensus estimates. The company also projected adjusted EPS of $5.55 to $5.80 roughly in line with forecasts.MedTech grew 10.4% organically in Q4, which was slightly below RBC's estimate. Established Pharmaceuticals rose 7%. These results supported total organic growth of 3.8% but excluding COVID-related sales.The brokerage said that the expectations have now reset and upside surprises in the second half could come from the US launch of the VOLT system in Electrophysiology. Additional growth could come from Structural Heart, Diabetes and potential M&A in Diagnostics and MedTech.Management remains committed to delivering double-digit EPS growth and cited confidence in operational execution and long-term demand trends, according to the note.RBC maintained an outperform rating for Abbott and lowered its price target to $135 from $147.Price: 107.66, Change: -0.95, Percent Change: -0.88","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2605340237","isCrawlerRequest":true}